Breast Cancer Coverage from Every Angle

New Trastuzumab Biosimilar Approved by the FDA

By: Sarah Jackson
Posted: Monday, June 17, 2019

On June 14, 2019, the U.S. Food and Drug Administration (FDA) approved trastuzumab-anns (Kanjinti) for all approved indications of the reference product trastuzumab (Herceptin) in the treatment of HER2-overexpressing adjuvant and metastatic breast cancers.

Trastuzumab-anns is a biosimilar to trastuzumab, a recombinant DNA-derived humanized monoclonal immunoglobulin G1 kappa antibody. The active ingredient of trastuzumab-anns is a humanized monoclonal antibody that has the same amino acid sequence, structure, and function as trastuzumab. Trastuzumab-anns has the same pharmaceutical dosage form and same strength after reconstitution as trastuzumab.

Trastuzumab-anns has proved to be highly similar to and to have no clinically meaningful differences from trastuzumab, based on a comprehensive totality of evidence that included extensive comparative analytic, pharmacokinetic, and clinical data. At the time of approval, trastuzumab-anns is the only trastuzumab biosimilar to incorporate the evaluation of a single transition in the clinical study, demonstrating similar safety and immunogenicity in patients who were previously treated with trastuzumab.

In the United States, trastuzumab-anns is approved for the adjuvant treatment of HER2-overexpressing node-positive or node-negative breast cancer as part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; with docetaxel and carboplatin; or as a single agent after multimodality anthracycline-based therapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.

Trastuzumab-anns is also indicated for metastatic breast cancer in combination with paclitaxel in the first-line treatment of HER2-overexpressing metastatic breast cancer or as a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.